Ball A P, Bartlett J G, Craig W A, Drusano G L, Felmingham D, Garau J A, Klugman K P, Low D E, Mandell L A, Rubinstein E, Tillotson G S
University of St Andrews, Fife, Scotland, UK.
J Chemother. 2004 Oct;16(5):419-36. doi: 10.1179/joc.2004.16.5.419.
The current document bestows an expert synopsis of key new information presented at the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) meeting in 2003. Data is presented on the socio-political aspects of and policies on antimicrobial prescribing, novel mechanisms of resistance in Streptococcus pneumoniae, and current epidemiological trends in global resistance. Novel information on new (and existing) antimicrobial agents--new penicillins, cephalosporins, monobactams and oxipenem inhibitors, ketolides, glycopeptides, fluoroquinolones (and hybrids), peptides, daptomycin, aminomethylcyclines, glycylcyclines, and newer formulations of agents such as amoxycillin-clavulanate--provides renewed hope that resistant pathogens can be controlled through use of more potent agents. Improved strategies for the use of existing antimicrobial agents, such as the use of high-dose regimens, short-course therapy, also may delay or reduce the development of resistance and preserve the value of our antibiotic armamentarium.
本文件提供了2003年第43届抗菌药物和化疗跨学科会议(ICAAC)上所展示的关键新信息的专家概述。内容涵盖抗菌药物处方的社会政治方面及政策、肺炎链球菌耐药的新机制,以及全球耐药的当前流行趋势。关于新型(和现有)抗菌药物的新信息——新型青霉素、头孢菌素、单环β-内酰胺类和氧青霉烯抑制剂、酮内酯类、糖肽类、氟喹诺酮类(及杂种)、肽类、达托霉素、氨基甲基环素、甘氨酰环素,以及阿莫西林-克拉维酸等药物的新剂型——让人们重新燃起希望,即通过使用更有效的药物可以控制耐药病原体。现有抗菌药物使用的改进策略,如高剂量方案、短程疗法的使用,也可能延缓或减少耐药性的产生,并保持我们抗生素库的价值。